China-based gene therapy specialist Lingyi Biotechnology Co., Ltd has entered into a comprehensive collaboration agreement with Zhejiang Jolly Pharmaceutical Co., Ltd. The partnership aims to leverage the respective strengths of both companies in equity, research and development (R&D), and sales.
Enhancing Drug Development and Commercialization
Under the terms of the agreement, Jolly Pharma will support Lingyi Bio in advancing drug research and development, regulatory filing, and commercialization. This collaboration will capitalize on Jolly Pharma’s strengths in capital and drug R&D to bolster Lingyi Bio’s efforts in these areas.
Leveraging Core Competencies for Market Expansion
Lingyi Bio, in turn, will utilize its existing advantages in drug discovery, optimization screening, and pharmacological efficacy to assist Jolly Pharma in drug development. This support is expected to aid Jolly Pharma in making strategic inroads into both domestic and international markets.
Confidentiality of Financial Details
The financial specifics of this strategic collaboration have not been disclosed, indicating the confidential nature of the agreement and the potential for significant impact on the gene therapy landscape in China.-Fineline Info & Tech
